Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have been given an average rating of "Moderate Buy" by the twenty-two analysts that are covering the company, Marketbeat reports. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $20.29.

ARVN has been the subject of several recent analyst reports. Guggenheim cut their target price on Arvinas from $32.00 to $16.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. UBS Group cut their target price on Arvinas from $74.00 to $21.00 and set a "buy" rating for the company in a research note on Thursday, May 15th. Citigroup cut their target price on Arvinas from $10.00 to $9.50 and set a "neutral" rating for the company in a research note on Monday, May 5th. The Goldman Sachs Group cut their target price on Arvinas from $12.00 to $8.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Finally, Leerink Partnrs cut Arvinas from a "strong-buy" rating to a "hold" rating in a research note on Sunday, June 1st.

Arvinas Price Performance

Shares of Arvinas stock opened at $7.47 on Friday. Arvinas has a 12 month low of $5.90 and a 12 month high of $34.11. The stock has a market capitalization of $545.24 million, a P/E ratio of -11.32 and a beta of 2.19. The business has a 50 day simple moving average of $7.45 and a two-hundred day simple moving average of $13.04.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $1.14 EPS for the quarter, beating the consensus estimate of ($0.93) by $2.07. Arvinas had a negative return on equity of 7.74% and a negative net margin of 10.92%. During the same period in the previous year, the firm earned ($0.97) earnings per share. The business's revenue was up 646.2% compared to the same quarter last year. As a group, research analysts anticipate that Arvinas will post -3.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Arvinas by 18.4% in the first quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company's stock valued at $58,703,000 after purchasing an additional 1,299,639 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Arvinas by 6.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company's stock valued at $78,656,000 after purchasing an additional 249,295 shares during the period. RTW Investments LP boosted its holdings in Arvinas by 19.8% in the fourth quarter. RTW Investments LP now owns 3,334,308 shares of the company's stock valued at $63,919,000 after purchasing an additional 551,979 shares during the period. T. Rowe Price Investment Management Inc. purchased a new position in Arvinas in the fourth quarter valued at $42,332,000. Finally, Alyeska Investment Group L.P. purchased a new position in Arvinas in the first quarter valued at $12,636,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.